Weekly update|Companies|Recruiting|Promote|Post a job

Korro Bio

Founded: 2019

Location: Cambridge, MA

Employee range: 50 - 200

Clinical stage: RD

Therapy area: Liver conditions

Drug types: HEP, NEU, OPH

Lead product: OPERA platform

Product link: https://www.korrobio.com/our-approach/

Funding: $116M B Jan 2022; $91.5M A Sep 2020; $4M seed Oct 2019

Investors: Atlas

korrobio.com

linkedin.com

job board

Short description:

RNA-editing Drugs

Drug notes:

Also RD CNS conditions, RD eye conditions

Long description:

Korro Bio is pioneering RNA editing as a therapeutic modality. RNA editing enables disease-causing mutations to be fixed before proteins are synthesized. Korro is using their Oligonucleotide Promoted Editing of RNA (OPERA) platform to identify the most effective RNA editing tools. OPERA revolves around co-opting the body’s natural base editing system, ADAR, a protein that makes targeted edits to a single RNA base, with Korro’s synthetic oligonucleotide guides to target specific RNA sequences. This circumvents permanently modifying a patient’s genome but still requires specificity and flexibility in delivery mechanisms. Korro’s focus areas include genetic diseases of the liver, central nervous system and eye.